TG and thyroid gland carcinoma: Unlike traditional methods that focus on tumor imaging and biomarker measurements (such as thyroid-cancer-specific thyroglobulin or calcitonin), metabolomics can monitor the treatment response using the analysis of metabolic reprogramming.